Milestone Scient Stock Price, News & Analysis

Milestone Scientific Inc. (NYSE:MLSS) has entered into a distribution agreement with Sweden & Martina for exclusive rights to market its STA Single Tooth Anesthesia System® in Italy, Spain, Portugal, and France. This strategic partnership taps into markets with over 180 million people. Sweden & Martina, a notable European dental distributor, will replace the current distributor in Italy. The STA system aims to improve patient experiences by offering painless injections. This collaboration aligns with Milestone's growth strategy in expanding its market reach.

Milestone Scientific (MLSS) has entered a distribution agreement with TEKMIKA Health Technologies to exclusively market its STA Single Tooth Anesthesia System^® in Brazil. This partnership allows TEKMIKA, a prominent distributor, to leverage its experience in the Brazilian dental market, which includes over 240,000 dentists. The STA system promises painless injections, shorter anesthesia wait times, and fewer complications. This expansion aligns with Milestone's strategy to penetrate new and existing markets, enhancing growth opportunities in Brazil, a significant dental market.

Milestone Scientific (NYSE: MLSS) has appointed Neal Goldman as the new Chairman of the Board of Directors, succeeding Leslie Bernhard. Goldman, who has been on the board since 2019, brings over 35 years of financial experience, previously serving in senior positions at various firms. CEO Arjan Haverhals expressed optimism about Goldman’s appointment, indicating it aligns with the company's growth phase. The board acknowledged Bernhard's significant contributions in corporate governance and business strategy, strengthening the company's foundation for future advancements in medical technology.

Milestone Scientific (NYSE: MLSS) reported a 34.4% sequential increase in sales for Q3 2022, reaching approximately $2.2 million. Year-over-year revenue growth also occurred, with a 28.6% increase excluding sales to China. Despite challenges in the dental segment due to geopolitical factors, the medical division is seeing progress with new distributors for the CompuFlo Epidural System and the introduction of a new CPT code in January 2023, aimed at enhancing reimbursement pathways. The company maintains a solid cash position of $9.8 million.

Milestone Scientific (NYSE:MLSS) will host a conference call on November 15, 2022, at 8:30 AM ET to discuss its Q3 financial results for the period ending September 30, 2022. The call will address the company’s progress and developments in its innovative drug delivery technologies. U.S. participants can join by calling 877-545-0523, while international callers can reach +1 973-528-0016. An audio replay will be available until November 29, 2022. For more information, visit the Investor Relations page.

Milestone Scientific (NYSE American:MLSS) announced that CEO Arjan Haverhals will present at the 2022 MicroCap Rodeo Windy City Roundup Conference in Chicago on October 12. His presentation is scheduled for 2:30 p.m. Central Time and will be webcast live. Haverhals will also engage in one-on-one meetings with qualified investors during the event. The conference aims to connect investors with over 60 microcap companies and explore key trends for 2023. Interested parties can register or request a meeting via email or the conference website.

Milestone Scientific (MLSS) has commenced sales of its CompuFlo Epidural disposables to UofL Health after a successful evaluation. This innovative system enhances patient outcomes in obstetric anesthesia and pain management across multiple departments. CEO Arjan Haverhals highlighted the validation this partnership represents. The CompuFlo system's clinical data shows significant reductions in complications and time savings for anesthesiologists, offering a compelling economic advantage for healthcare facilities. This collaboration positions Milestone for future growth in the medical technology space.

Milestone Scientific (NYSE: MLSS) announced its Q2 2022 financial results, reporting revenues of $1.6 million, down from $2.4 million in Q2 2021. A significant decrease in dental sales, particularly in China, and the impact of the Russia-Ukraine conflict contributed to this decline. Gross profit fell to $681,000 (41% of revenue) due to a $430,000 allowance on finished goods. The net loss was $2.9 million, unchanged from the previous year. Despite challenges, Milestone is expanding its CompuFlo® Epidural System and is optimistic about future revenue growth, supported by $11 million in cash and cost reductions.

Milestone Scientific (NYSE:MLSS) announced a conference call scheduled for August 16, 2022, at 8:30 AM ET to discuss its Q2 2022 financial results. The call will cover the company’s corporate progress and other developments. Interested parties can join via telephone or listen to a webcast on their website. An audio replay of the call will be available until August 30, 2022. Milestone Scientific focuses on innovative injection technologies designed for medical, dental, and cosmetic applications, enhancing patient comfort and safety.